Clinuvel Pharmaceuticals LimitedASX: CUV

CLINUVEL develops proprietary ZEROKIN device

· Issued by Clinuvel Pharmaceuticals Limited via ASX

Filed with ASX ·

On 6ix: 6ix.com/news/clinuvel-develops-proprietary-zerokin-device

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call

A S X A N N O U N C E M E N T ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9 ASX Announcement PAGE 1 OF 3 CLINUVEL develops proprietary ZEROKIN™ device Single-use administration device for controlled-release formulations Executive Summary • ZEROKIN™ novel single-use...

View Attachment

6ix hasn’t read this filing yet.

Clinuvel Pharmaceuticals Limited on 6ix

Earlier from Clinuvel Pharmaceuticals

Later from Clinuvel Pharmaceuticals

All Clinuvel Pharmaceuticals news releases